DermTech Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DermTech in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DermTech stock.
View analyst ratings for DermTech or view top-rated stocks.

Wall Street analysts have given DermTech a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but DermTech wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

DermTech is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for DermTech.

DermTech will be holding an earnings conference call on Wednesday, August 4th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

DermTech, Inc. (NASDAQ:DMTK) posted its quarterly earnings results on Thursday, May, 13th. The company reported ($0.49) EPS for the quarter, missing the Zacks' consensus estimate of ($0.47) by $0.02. The business had revenue of $2.52 million for the quarter, compared to analyst estimates of $2 million. DermTech had a negative trailing twelve-month return on equity of 38.55% and a negative net margin of 631.63%.
View DermTech's earnings history.

DermTech's stock was trading at $14.37 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DMTK shares have increased by 134.2% and is now trading at $33.66.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued 1 year target prices for DermTech's shares. Their forecasts range from $20.00 to $79.00. On average, they anticipate DermTech's stock price to reach $56.00 in the next twelve months. This suggests a possible upside of 66.4% from the stock's current price.
View analysts' price targets for DermTech or view top-rated stocks among Wall Street analysts.

Some companies that are related to DermTech include Fulgent Genetics (FLGT), Veracyte (VCYT), Burning Rock Biotech (BNR), RadNet (RDNT), Castle Biosciences (CSTL), Genetron (GTH), Renalytix AI (RNLX), Personalis (PSNL), Celcuity (CELC), Centogene (CNTG), Exagen (XGN), Enzo Biochem (ENZ), Viridian Therapeutics (VRDN), Progenity (PROG) and OpGen (OPGN).
View all of DMTK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other DermTech investors own include Pfizer (PFE), CrowdStrike (CRWD), DocuSign (DOCU), ONEOK (OKE), Intel (INTC), U.S. Xpress Enterprises (USX), Valero Energy (VLO), Momo (MOMO), AVEO Pharmaceuticals (AVEO) and Camping World (CWH).

DermTech trades on the NASDAQ under the ticker symbol "DMTK."

DermTech's stock is owned by a number of retail and institutional investors. Top institutional investors include Kornitzer Capital Management Inc. KS (0.75%), Avalon Investment & Advisory (0.25%), Alliancebernstein L.P. (0.09%) and Kovack Advisors Inc. (0.02%). Company insiders that own DermTech stock include Burkhard Jansen, Claudia Ibarra, Enrico Picozza, John Dobak, Kevin M Sun, Matthew L Posard, Mutual Insurance Co Donegal, Rtw Investments, Lp, Scott R Pancoast and Todd Michael Wood.
View institutional ownership trends for DermTech.

DMTK stock was acquired by a variety of institutional investors in the last quarter, including Avalon Investment & Advisory, Kornitzer Capital Management Inc. KS, Alliancebernstein L.P., and Kovack Advisors Inc.. Company insiders that have bought DermTech stock in the last two years include Enrico Picozza, Matthew L Posard, Mutual Insurance Co Donegal, and Rtw Investments, Lp.
View insider buying and selling activity for DermTech or or view top insider-buying stocks.

Shares of DMTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DMTK stock can currently be purchased for approximately $33.66.

DermTech has a market capitalization of $974.12 million and generates $5.89 million in revenue each year. The company earns $-35,250,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis.

DermTech employs 114 workers across the globe.

The official website for DermTech is www.dermtech.com.

DermTech is headquartered at 11099 N. Torrey Pines Road Suite 100, La Jolla CA, 92037.

DermTech's mailing address is 11099 N. Torrey Pines Road Suite 100, La Jolla CA, 92037. The company can be reached via phone at 858-450-4222 or via email at [email protected]